This triple-action approach may give Retatrutide an edge in weight loss potential, though Tirzepatide already has approval and proven real-world use
The SELECT trial (NCT03574597) regarding cardiovascular outcomes is estimated to be completed by 2023
Wider use of diagnostic tools (like HbA1c testing) combined with greater awareness improves early detection - translating to larger treated populations
Maintaining adequate fluid intake is important, though individuals with conditions requiring fluid restriction such as heart failure or chronic kidney disease should follow the specific guidance given by their clinical team
Gilbert MP, Skelly J, Hernandez AF, Green JB, Krychtiuk KA, Granger CB, et al
The brand states the product is manufactured in an FDA-registered, GMP-certified facility - FDA facility registration is a legal requirement for supplement manufacturers, not an endorsement or product-level approval